⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of OranssiBio (Shanghai) Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
OranssiBio (Shanghai) Co., Ltd.
↗Shanghai, China
OranssiBio is a high-end research, development, and manufacturing service provider specializing in cell and gene therapies (CGT). The company operates as an integrated CRO + CDMO platform, supporting global biopharmaceutical companies and research institutions across the entire development lifecycle, from early-stage discovery to commercial-scale manufacturing.
Their core technology platforms include mRNA-LNP, lentiviral vectors (LVV), plasmids, exosomes, and cell therapy. The company emphasizes GMP compliance, international regulatory standards (FDA, EMA, NMPA), and scalable production capabilities to accelerate the development of transformative advanced medicines.
CLASSIFICATION
SIZE & FINANCIALS
Ownership:private
Status:operating
PIPELINE
Stage:Discovery
Lead Drug Stage:Service provider (not applicable)
Modalities:Cell therapy, Gene therapy, mRNA, Viral vectors, Exosomes
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Global biopharmaceutical companies and research institutions (clients)
COMPETITION
Position:Emerging
Competitors:WuXi AppTec, Lonza, Thermo Fisher Scientific, Catalent
LINKS
Website:oranssibio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with OranssiBio (Shanghai) Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.